InvivoGen’s Post

I am delighted to announce the publication of our latest paper, "Self-adjuvanted L-arginine-modified dextran-based nanogels for sustained local antigenic protein delivery to antigen-presenting cells and enhanced cellular and humoral immune responses." I would like to express my appreciation to Melody Jin Teng Chung, as well as my supervisor, Professor Ying Chau, for their invaluable contributions to this project. Our research endeavors to propel cancer vaccine development by tackling critical challenges, such as the poor immunogenicity of tumor antigens and their rapid clearance by the immune system. We have successfully engineered dextran-based nanogels that not only augment antigen uptake, storage, and presentation but also facilitate the maturation of antigen-presenting cells (APCs). For those interested in delving deeper into our groundbreaking research, please find the paper at the following link: https://lnkd.in/gVbkjYQW #cancervaccine #nanogels #immunotherapy #research

🧬 Exploring the Power of Peptide Pools in Immunology Research🔬 Peptide pools are mixtures of short peptide sequences that span entire proteins or represent key immunodominant epitopes. They are essential for stimulating antigen-specific CD4+ and CD8+ T cells, enabling the detection and quantification of activated T cells. Key Benefits: ✳️ Simple and efficient ✳️ Cost-effective ✳️ Versatile applications in vaccine development, immune cell monitoring, and diagnostic assays In this protocol, you will learn how to: -Prepare peptide pool stocks -Set up suspensions of peripheral blood mononuclear cells (PBMCs) -Perform in vitro stimulation and detect antigen-specific T cells using flow cytometry and ELISpot assays. Peptide pools are powerful tools for advancing your research in immunology. Feel free to contact me if you'd like to test our T Cell Media and EasySep Isolation Kits! https://lnkd.in/eQ_SDTzB #Immunology #VaccineDevelopment #TcellResearch #PeptidePools 

I am excited to share this new review, which was written with my colleague Sheila Keating, PhD MSPH at Gigagen.  In this review we detail the history of antibody discovery and the current applications of antibody engineering technologies. As we consider the future of antibody therapy in the infectious disease space, we highlight the benefits of applying AI/ML to accelerate antibody discovery and development as well as the potential of novel polyclonal antibody therapies.

A fun fact to mark the International Day of Immunology! 🌟 Did you know that the dynamics of antigen-specific T cells during immune checkpoint blockade is associated with clinical outcome? This study conducted by Gaiβler et al. investigated the dynamics of circulating Melanoma-Associated Epitope (MAE)-specific CD8+ T cell populations in the blood of melanoma patients before and during anti-PD-1 treatment, and their relationship with clinical outcome. To study a large number of different MAE-specific CD8+ T cell populations the authors used a library of 167 pMHC multimers (MAE-specific DNA barcoded Dextramer reagents) in a high-throughput approach. The study identified individual MAE-specific CD8+ T cell populations that correlated with overall survival, suggesting their potential as biomarkers for patient response to immune checkpoint blockade therapy. Find the link to the article in the comments!👇👇 We’ll also put a link to one of our blog posts where you can read more about the patient response to checkpoint inhibitors. #Immunotherapy #CheckpointInhibitors #CheckpointBlockade #Immunology #flowcytometry #DayOfImmunology

I am excited to share a publication related to my thesis work! T cells are incredible cells that confer protective immunity by directly killing infected or cancerous cells. Vaccines and immunotherapies like CAR-T educate these cells to kill target cells. Unfortunately, T cells don't always persist long-term, and mechanisms that are readily available for intervention are not well known. Our research finds that ER stress is associated with T cell activation and that pathways that mediate it, such as ERAD, are necessary for T cell persistence through the regulation of T cell metabolism. Using publicly available data, I translated our findings to human T cells during CAR-T therapy and bispecific immune cell engager therapy. I found that alleviating ER stress is already associated with interventions that improve T cell functionality in these settings. We hope these findings illuminate ER stress, an under-appreciated pathway in T cells, as a relevant pathway for further study and possibly intervention in therapeutic settings. We are thankful to all the collaborators who helped make this possible. https://lnkd.in/eHaxbp3U

'Ubiquitin-specific peptidase 39 (USP39), a component of the RNA splicing machinery, maintained RNA-splicing-mediated CTLA-4 expression to control Treg cell function. Mechanistically, lactate promoted USP39-mediated RNA splicing to facilitate CTLA-4 expression in a Foxp3-dependent manner.' #immunology #Metabolism #Treg #CTLA4 https://lnkd.in/d8-5TwpM

𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐨𝐮𝐧𝐝𝐮𝐩 "𝐌𝐚𝐬𝐬𝐢𝐯𝐞𝐥𝐲-𝐦𝐮𝐥𝐭𝐢𝐩𝐥𝐞𝐱𝐞𝐝 𝐞𝐩𝐢𝐭𝐨𝐩𝐞 𝐦𝐚𝐩𝐩𝐢𝐧𝐠 𝐭𝐞𝐜𝐡𝐧𝐢𝐪𝐮𝐞𝐬 𝐟𝐨𝐫 𝐯𝐢𝐫𝐚𝐥 𝐚𝐧𝐭𝐢𝐠𝐞𝐧 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲" The massively multiplexed epitope mapping techniques discussed in the paper offer significant benefits to scientists by 𝐞𝐧𝐡𝐚𝐧𝐜𝐢𝐧𝐠 𝐭𝐡𝐞 𝐞𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐲, 𝐚𝐜𝐜𝐮𝐫𝐚𝐜𝐲, 𝐚𝐧𝐝 𝐬𝐜𝐚𝐥𝐞 𝐨𝐟 𝐞𝐩𝐢𝐭𝐨𝐩𝐞 𝐢𝐝𝐞𝐧𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧, which is crucial for understanding immune responses and designing vaccines and therapeutic antibodies. These techniques, including phage display, peptide microarrays, and deep mutational scanning, provide 𝐡𝐢𝐠𝐡-𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐩𝐮𝐭 𝐜𝐚𝐩𝐚𝐛𝐢𝐥𝐢𝐭𝐢𝐞𝐬, 𝐥𝐨𝐰𝐞𝐫 𝐜𝐨𝐬𝐭𝐬, 𝐚𝐧𝐝 𝐭𝐡𝐞 𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐭𝐨 𝐡𝐚𝐧𝐝𝐥𝐞 𝐜𝐨𝐦𝐩𝐥𝐞𝐱 𝐚𝐧𝐝 𝐥𝐚𝐫𝐠𝐞 𝐝𝐚𝐭𝐚𝐬𝐞𝐭𝐬, thereby accelerating research in virology, immunology, and related fields. Paper and picture reference: Hu, D., & Irving, A. T. (2023). Massively-multiplexed epitope mapping techniques for viral antigen discovery. Frontiers in Immunology, 14, 1192385. #EpitopeMapping #PeptideMicroarrays #peptides

Our CEO John Montana spoke with BioWorld News following the announcement of our official company launch and €75 million (US$81 million) Series A financing to advance neutralizing antibodies targeting proinflammatory molecules that drive inflammatory and fibrotic diseases. In the interview John outlines how the funding will be used over the next three years to drive phase IIa data generation across three indications.   ➡️CAL-101, targeting S100A4, is currently in a Phase Ib trial, with results anticipated in the first half of this year. Future plans include Phase IIa proof-of-concept (PoC) studies addressing fibrotic and chronic inflammatory diseases. ➡️CAL-102, targeting oxidised phospholipids (OxPL), is progressing through preclinical development for myocardial infarction induced reperfusion injury, with Phase I development slated for 2025. The funding will propel its progression to generate Phase IIa clinical PoC data in a comparable timeframe to the CAL101 clinical readouts. ➡️CAL-103 will also progress to a Phase Ib biomarker data readout in an inflammatory indication by mid 2026. Read the full interview here: https://rb.gy/pyapsv #Biotech #Biopharma #Immunology #Clinical #Innovation

Introducing our eBook on Microplate Reader Solutions for Virology and Immunology. We're dedicated to supporting scientists in their research on virus cellular response and the development of therapies and vaccines for. From cell line development to imaging, microplate readers, washers, and GxP compliant data acquisition and analysis software, we offer validated and compliant lab solutions to accelerate your work. Download the eBook now and join us in advancing virology and immunology research! 💪💉🔬 #VirologyResearch #ImmunologyResearch #LabSolutions

The coronavirus family, identified initially in 1960, includes several strains that infect humans, with SARS-CoV-2 causing the COVID-19 pandemic since its emergence in late 2019. These viruses, characterized by their crown-like spikes, enter human cells via ACE2 receptors, widely distributed in various tissues. Their RNA nature and high mutation rates pose challenges for vaccine development. Monoclonal antibody therapies have shown promise in treating COVID-19 by targeting viral proteins, although they have limitations such as short-term effectiveness and lung-specific action. Recently, researchers have developed OligoBinders, protein nanoparticles inspired by amyloid structures, which effectively prevent SARS-CoV-2 from binding to ACE2 receptors. These OligoBinders are biocompatible, stable, and easy to produce, offering a potentially valuable tool in combating COVID-19 by blocking viral entry into human tissues. To know more, follow Scioverleaf and click the link below https://lnkd.in/g2kKDPbR